Republic Services Inc
Change company Symbol lookup
Select an option...
RSG Republic Services Inc
AAPL Apple Inc
CYBN Cybin Inc
LEN.B Lennar Corp
STLD Steel Dynamics Inc
GOEVW Canoo Equity Warrant Exp 21st Dec 2025 *W EXP 12/21/2025
GNBT Generex Biotechnology Corp
MFA MFA Financial Inc
GOOG Alphabet Inc
ADILW Adial Pharmaceuticals Equity Warrants Exp 31 July 2023 *W EXP 07/31/2023
Go

Industrials : Commercial Services & Supplies | Large Cap Blend
Company profile

Republic Services, Inc. is a provider of environmental services in the United States. Through its subsidiaries, transfer stations, recycling centers and landfills, it focuses on providing effective and reliable environmental services and solutions to make proper recycling and waste disposal for its customers. The Company operates through three segments Group 1, Group 2 and Environmental Solutions. Group 1 segment primarily consists of geographic areas located in the western United States. Group 2 segment primarily consists of geographic areas located in the southeastern and mid-western United States, and the eastern seaboard of the United States. Its Environmental Solutions segment provides environmental solutions for daily operations of industrial, petrochemical and refining facilities across the United States and Canada. The Company is engaged in 77 landfill gas-to-energy and other renewable energy projects and had post-closure responsibility for 124 closed landfills.

Premarket

Last Trade
Delayed
$132.10
-1.31 (-0.98%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$133.41
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
76

10-day average volume:
1,211,841
76

Evofem Biosciences Applauds U.S. House of Representatives for Passing The Right to Contraception Act

8:47 am ET July 22, 2022 (PR Newswire) Print

Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today applauded the 228 members of the U.S. House of Representatives who voted to pass legislation to safeguard access to contraceptives entitled The Right to Contraception Act.

https://mma.prnewswire.com/media/780907/Evofem_Biosciences_Logo.jpg

"Today we applaud the U.S. House of Representatives for passing The Right to Contraception Act, which would codify into law the fundamental right to safe and easy access to contraception," said Saundra Pelletier, Chief Executive Officer of Evofem Biosciences. "Too often, women are at the mercy of insurance companies and industry middlemen that have posted record profits, yet refuse to cover contraception or put up significant barriers to access. Providing women with their choice of contraception should not be up for debate."

About Evofem Biosciences Evofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea. The Company's first FDA-approved product, Phexxi(R) (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. The Company expects to report top-line data this fall from its registrational Phase 3 EVOGUARD clinical trial evaluating Phexxi for two potential new indications - prevention of chlamydia and prevention of gonorrhea in women. Learn more at phexxi.com and evofem.com.

Phexxi(R) is a registered trademark of Evofem Biosciences, Inc.

Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, including, without limitation, evaluations and judgments regarding Evofem, its products, its product candidates and their development, demand for Evofem's products and product candidates and The Right to Contraception Act. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward- looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences' assets and business are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 10, 2022 and its Quarterly Report on Form 10-Q filed with the SEC on May 10, 2022. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

Investor Relations Contact Media Contact
Amy Raskopf                media@evofem.com
araskopf@evofem.com
Mobile: (917) 673-5775

https://c212.net/c/img/favicon.png?sn=LA24488&sd=2022-07-22

View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-applauds-us-house-of-representatives-for-passing-the-right-to-contraception-act-301591498.html

SOURCE Evofem Biosciences, Inc.

https://rt.prnewswire.com/rt.gif?NewsItemId=LA24488&Transmission_Id=202207220847PR_NEWS_USPR_____LA24488&DateId=20220722

comtex tracking

COMTEX_410742745/1005/2022-07-22T08:47:08

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.